Half-Year 2022 Financial and Clinical Trials Update
Tecentriq
Anti-PD-L1 cancer immunotherapy - SCCHN and melanoma
Indication
Phase/study
# of patients
Design
Primary endpoint
Status
CT Identifier
ARM A: Tecentriq 1200mg q3w
ARM B: Placebo
Event-free survival and overall survival
FPI Q1 2018
Recruitment completed Q1 2020
Adjuvant squamous cell carcinoma of the head and neck (SCCHN)
Phase III
IMvoke010
N=406
NCT03452137
Roche
¹In collaboration with Exelixis; 2Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; ³ Project Orbis-FDA framework for concurrent submission and review of oncology products among international partners
SCCHN-squamous cell carcinoma of the head and neck; PD-L1-Programmed cell death-ligand 1; AACR-American Association for Cancer Research
90
00
OncologyView entire presentation